Prometheus Biosciences is a biotechnology business based in the US. Prometheus Biosciences shares (RXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Prometheus Biosciences employs 72 staff and has a trailing 12-month revenue of around $7.2 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $113.66 |
|---|---|
| 52-week range | $21.50 - $122.75 |
| 50-day moving average | $86.85 |
| 200-day moving average | $51.80 |
| Wall St. target price | $146.18 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.78 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $113.66 from 2023-01-31
| 1 week (2023-01-25) | -4.58% |
|---|---|
| 1 month (2022-12-30) | 3.33% |
| 3 months (2022-11-02) | 122.43% |
| 6 months (2022-08-02) | 172.11% |
| 1 year (2022-02-02) | 216.43% |
|---|---|
| 2 years (2021-01-29) | N/A |
| 3 years (2020-01-29) | N/A |
| 5 years (2018-01-29) | N/A |
| Revenue TTM | $7.2 million |
|---|---|
| Gross profit TTM | $-59,298,000 |
| Return on assets TTM | -27.21% |
| Return on equity TTM | -53.74% |
| Profit margin | 0% |
| Book value | $5.56 |
| Market capitalisation | $5.5 billion |
TTM: trailing 12 months
We're not expecting Prometheus Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
Prometheus Biosciences's shares were split on a 1:100 basis on 31 October 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Prometheus Biosciences shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Prometheus Biosciences shares which in turn could have impacted Prometheus Biosciences's share price.
Prometheus Biosciences, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.